Navigation Links
VacChina 2010 - A Premium Event to Define the Vaccine Industry in Asia
Date:6/25/2010

SHANGHAI, June 25 /PRNewswire-Asia/ --

"Life or death for a young child too often depends on whether he is born in a country where the vaccines are available or not."

-- Nelson Mandela

Hosted by Global Leaders Institute, world vaccine industry leaders will convene at VacChina 2010 on Sept 15 and 16 in Shanghai. The two-day executive summit will explore the major partnering opportunities in the vaccine industry in China. The goal of the summit is to bridge the China vaccine industry with the world in terms of vaccine R&D and production innovation and address needs of the entire industry to improve vaccine quality and safety.

At the end of 2009, the vaccine industry raised so much concern worldwide that the headlines of the business media were occupied by various kinds of news about vaccine enterprises. For example, Sinovac Biotech Co., Ltd. successfully landed the Nasdaq, then Simcere, a pharmaceutical company based in Jiangsu Province and listed on the NYSE, announced a 50.8% stake in Ealong Biotech and took control of the latter, and finally Novartis, the world-famous pharmaceutical company headquartered in Switzerland, acquired an 85.0% equity in Tianyuan Bio-Pharmaceutical, a vaccine producer, for RMB850M. These deals indicate that the investors and foreign pharmaceutical giants have not slowed down their pace to enter China's vaccine market, even in the face of this economic recession.

Over 150 attendees from vaccine producers home and abroad will gather under the same roof to elaborate on themes on the evolution of China's vaccine market and make comparisons to other emerging markets. Other topics will include the role of vaccines in the overall healthcare reform efforts in China and associated pricing strategies, future prospects of foreign vaccine products into China's EPI, China's intellectual property landscape, vaccine manufacturing in China, quality and safety from design to operations, bridging the gap between R&D and production, low cost novel purification platforms for vaccine production capacity and quality etc.

Renowned presenters speaking at the main conference on Sept 15 and 16 include Weidong Yin from Sinovac China, Xiaohang Ding from Zhejiang Tianyuan Bio-Pharmaceutical, Bing Zeng from Sinopharm, Xiaohan Du from Simcere Pharmaceutical Group, Pierre Trotemann from Sanofi Pasteur, Shou-Bai Chao from MedImmune, etc.

    For more information, please contact:

     Daniel Chen
     Tel:   +86-21-3251-6046

    Or visit the website http://www.globaleaders.com/en/2010/vac/index.asp


'/>"/>
SOURCE Global Leaders Institute
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Myelin Removal Beads: Premium Efficiency for Neural Cell Separations and Antibody Stainings
2. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
3. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
4. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
5. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
6. Influenza is Leading Cause of Vaccine-Preventable Deaths for Kids; Despite CDC Recommendations, Moms Still Dont Vaccinate
7. U.S. Preventive Medicine Acquires Specialty Disease Management
8. For Most, Good Oral Care Does More Than Antibiotics to Prevent Dental-Related Heart Problems, Reports the Harvard Heart Letter
9. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
10. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
11. Inhaled Steriods Used as Preventive Treatment Post 9/11
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017  Cornerstone Pharmaceuticals, Inc., a ... milestone today.  Following successful End-of-Phase I (EOP1) ... and Drug Administration (FDA), the Company has ... path forward to conduct pivotal trials of ... acute myeloid leukemia (AML) and pancreatic cancer. ...
(Date:3/23/2017)... March 23, 2017 Piramal ... Limited, anuncia el nombramiento de Stuart E. ... plataforma de servicios integrados completa para su base ... cargo clave en el crecimiento y ejecución de ... responsable de impulsar todas las actividades de desarrollo ...
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... The ... from the NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart ... granted to organizations that have excellent programs for the delivery and improvement of ...
(Date:3/23/2017)... ... March 23, 2017 , ... March 23, 2017 - ... to easily reprint customer invoices, bills, statements and other correspondence when they have ... needed to retrieve and print the documents and batch them for efficient handling. ...
(Date:3/23/2017)... OR (PRWEB) , ... March 23, 2017 , ... Sharon ... Water, Global Climate Change and Your Health on VoiceAmerica, recently talked on her program ... she also used the occasion to remind listeners of an important distinction. World Water ...
(Date:3/23/2017)... ... March 23, 2017 , ... Corra Group is ... competitive pricing. Verisys through its FACIS and other services maintains the ... actions. , “We are delighted to be able to offer these various products ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April 4, 2017 ... will the new EU MDR language change the way manufacturers approach CERs? ...
Breaking Medicine News(10 mins):